Coronary angioplasty has dramatically influenced the current practice of cardiology. Introduced only 10years ago, it is now widely used as a means of revascularizing symptomatic patients with coronary artery disease. It is currently considered the optimal therapy for nearly one half of patients needing a revas cularization procedure. Recent studies suggest that the technique can be satis factorily and effectively used in elderly patients, those with multivessel disease, as well as patients with recent myocardial infarctions. Despite these broadening indications, success rates have risen to more than 90% in most centers while mortality has remained low (1%). Angioplasty is still limited by restenosis or renarrowing of the dilated vessel that occurs in 25-35% of patients within the first six months. Repeat angioplasty is successful in almost all patients and can even be repeated on multiple occasions if necessary. Long-term follow-up shows a low incidence of subsequent death or non-fatal myocardial infarction with a majority of patients asymptomatic after five years. New techniques are now being developed to permit recannulization of chronically totally occluded blood vessels as well as reduce abrupt vessel closure and early restenosis. These tech niques include laser angioplasty, atherectomy and intravascular stents. The growth and expansion of angioplasty has given the cardiovascular physician an important new treatment modality for symptomatic patients with coronary artery disease. Its impact on the practice of medicine will be felt for many years to come.
disease, compared to 46% in a more recent registry. While multi-lesion dilatations were unusual initially (9.5%) they have become much more common recently (40%). Cur rently, treated patients are older, have higher incidence of prior MI, prior by-pass surgery, congestive heart failure, diabetes and lower ejection fractions.
In spite of changes in patient selection, the success rate has significantly risen. At least one lesion was successfully dilated in 91% of the cases, and all lesions were successfully dilated in 82% of patients in the current angioplasty registry. This com pares to 68% and 63% earlier. This higher success rate was associated with a lower need for emergency by-pass surgery (3.9% vs 6.0%) and an equivalent rate of non-fatal myocardial infarction (4.3% vs 5.1%) and death (1% vs 0.7%).
Using the current guidelines that now include single and multi-vessel disease, approximately 50% of patients presenting to our institution are candidates for revas cularization, using the even more aggressive approach that attempts to dilate only the "culprit" lesion , presumably responsible for the patient's symptoms, more than 75% of patients referred for revascularization could receive an angioplasty rather than by pass surgery. Perhaps the greatest limitation of angioplasty is restenosis that continues to average 30 to 35% in most centers.5 The majority of patients present with recurrent angina at 3 to 4 months after PTCA and redilatation has shown to be highly effective and asso ciated with a low risk of complications. Clinical studies have shown that male gender, unstable angina, diabetes, hypercholesterolemia, cigarette smoking, multi-vessel disease, ostial, left anterior descending or right coronary lesions and lesions of the by-pass grafts are most likely to develop restenosis. While the mechanism of restenosis is unknown, it seems likely that it is due to the traumatic damage that occurs following angioplasty.
As we have previously shown, angioplasty results in severe damage to the vessel wall with splitting of the neo-intimal plaque and stretching the vessel.6 There is an immediate accumulation of platelets that is directly related to the degree of vascular damage. Ex perimentally, anti-platelet regimens can significantly reduce the incidence of restenosis by preventing platelet accumulation. However, disappointingly, aggressive therapy with anti-plate!et drugs or anti-coagulants, as well as calcium antagonists have not altered the incidence of restenosis in clinical trials. Thus current research is more actively in vestigating the stimulus for smooth muscle cell migration and proliferation in the role of monocytes and macrophages in this process.
If a patient does not develop restenosis, or is successfully redilated, the patient's long-term outcome is excellent, particularly, with single vessel disease.7,9 The overall five year survival of patients entered in the NHLBI, PTCA registry was 92% and 78% of the patients were asymptomatic at five years. This is also supported by the excellent long-term outcome of the 169 patients initially studied by Dr. Gruentzig. Actuarial event-free survival (freedom from death, MI or by-pass surgery) was 79% at six years and 67% of the patients were asymptomatic. The one year, event-free survival in pa tients with multi-vessel disease is also excellent (78%) with 70% of the multi-vessel patients asymptomatic at one year.13 Reports from many centers now reaffirm that angioplasty can be successfully and safely applied to patients with multi-vessel disease. Whether this form of therapy is better than by-pass surgery, it has not yet been shown by any randomized trial, however, three large multi-center clinical trials are now under way in the United States to examine this question. Intravascular stints or metallic expandable coils placed during angioplasty have recently been used in Europe and preliminary reports indicate they are highly effective in reducing restenosis.12 In addition, they have been effective in managing patients who develop abrupt vessel closure due to vascular dissection. The major complication of these devices has been thrombotic occlusion, necessitating prolonged anti-coagulation.
Again, experience is limited, however, the potential in treating angioplasty complications seems great.
The future of angioplasty and other interventional techniques is extremely bright and it is not unreasonable to expect that coronary angioplasty and related techniques will become the primary therapy for the majority of symptomatic patients not adequate ly treated with medical therapy. It also seems likely that by-pass surgery will continue to flourish, but be reserved for patients in whom angioplasty is not possible or has been demonstrated to be unsastifactory. 
